文献速递眼底病与葡萄膜炎

比较阿柏西普、贝伐珠单抗与雷珠单抗治疗糖尿病黄斑水肿的随机临床试验中血压与尿白蛋白肌酐比的变化

Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

该研究为随机临床试验的预设二次分析,纳入660例糖尿病黄斑水肿且至少一眼视力20/32或更差的参与者,比较阿柏西普、贝伐珠单抗与雷珠单抗治疗2年间血压及1年时尿白蛋白肌酐比的变化。结果显示三组间平均动脉压变化(整体P=0.69)及尿白蛋白肌酐比分类变化(整体P=0.29)均无显著差异。

要点

  • 三组2年平均动脉压变化分别为阿柏西普-1.2±15、贝伐珠单抗-1.8±13.5、雷珠单抗-2.6±14.4 mm Hg,整体P=0.69。
  • 52周时尿白蛋白肌酐比分类变化在三组间无差异,整体P=0.29。
  • 作者结论认为,在糖尿病黄斑水肿患者中,三种抗VEGF治疗对血压或反映肾功能的尿白蛋白肌酐比变化似无治疗组间差异。

核心结论

  • 在糖尿病黄斑水肿患者中,接受阿柏西普、贝伐珠单抗或雷珠单抗治疗,血压或反映肾功能的尿白蛋白肌酐比变化似无治疗组间差异。

研究设计与样本

  • 随机临床试验的预设二次分析,由糖尿病视网膜病变临床研究网络(DRCR.net)纳入660例糖尿病黄斑水肿且至少一眼视力20/32或更差的参与者。
  • 患眼接受玻璃体腔内注射2.0 mg阿柏西普、1.25 mg贝伐珠单抗或0.3 mg雷珠单抗,依据结构化再治疗方案治疗2年。
  • 主要结局指标为2年时血压变化和1年时尿白蛋白肌酐比(UACR)变化。

主要发现

  • 基线时95例(14%)血压正常,220例(33%)临界性血压升高,206例(31%)轻度血压升高,139例(21%)中度血压升高。
  • 从基线至2年平均动脉压平均变化:阿柏西普组-1.2±15 mm Hg,贝伐珠单抗组-1.8±13.5 mm Hg,雷珠单抗组-2.6±14.4 mm Hg,整体P=0.69。
  • 基线时247例(38%)无白蛋白尿(<30 mg/g),195例(30%)微量白蛋白尿(30-300 mg/g),212例(32%)大量白蛋白尿(>300 mg/g)。
  • 52周访视时尿白蛋白肌酐比分类变化在各治疗组间无差异,整体P=0.29。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare blood pressure and urine albumin-creatinine ratio over time for participants receiving aflibercept, bevacizumab, or ranibizumab. METHODS: Preplanned secondary analyses from a randomized trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME). The Diabetic Retinopathy Clinical Research Network (DRCR.net) enrolled 660 participants with DME and visual acuity 20/32 or worse in at least one eye. Eyes received intravitreous injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab based on a structured retreatment protocol over 2 years. Main outcome measures were (1) a change in blood pressure at 2 years, and (2) a change in urine albumin-creatinine ratio (UACR) at 1 year. RESULTS: At baseline, 95 participants (14%) had normal blood pressure, 220 (33%) had borderline blood pressure elevation, 206 (31%) had mild blood pressure elevation, and 139 (21%) had moderate blood pressure elevation. Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69). At baseline 247 participants (38%) had no albuminuria (<30 mg/g), 195 (30%) had microalbuminuria (30-300 mg/g), and 212 (32%) had macroalbuminuria (>300 mg/g). Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29). CONCLUSIONS: There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Glassman AR, Liu D, Jampol LM, et al. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018. PMID: 29625440. doi:10.1167/iovs.17-22853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。